StemLifeLine has announced that it received approval from the California Department of Health Services (CDHS) to engage in the operation of a tissue bank in accordance with Division 2, Chapter 4.1 of the Health and Safety Code.
With this Tissue Bank license, individuals who have undergone in vitro fertilization (IVF) may now use StemLifeLine’s service to develop personal stem cell lines from their remaining stored embryos. StemLifeLine is the first life sciences company to offer this service through IVF centers.
“Developing a personal stem cell line is like buying insurance for the future,” stated Ana Krtolica, Ph.D., cofounder, CEO and chief scientific officer (CSO) of StemLifeLine.
“Until now, there have been only three options for frozen embryos remaining from the in vitro fertilization process. They could be donated to research, given up for ‘adoption’ to other couples or discarded. With our approved California Tissue Bank license, we can now offer IVF patients the option to derive and preserve their own stem cell line for their future use,” Krtolica said.
Using a multi-stage process, and patented technologies, StemLifeLine works to derive the stem cells from frozen embryos remaining from in vitro fertilization. If successful, the stem cells are then grown or “cultured” in the laboratory under clean lab conditions, which follow current good tissue practices (cGTP).
After working with StemLifeLine, clients will have access to their own high quality, genetically-matched stem cells, which they may use in the future if stem cell therapies become available.